06:55 AM EDT, 05/06/2024 (MT Newswires) -- ADC Therapeutics ( ADCT ) said Monday the initial data from a phase 2 clinical study evaluating its loncastuximab tesirine-lpyl cancer drug candidate Zynlonta showed a high response rate in treating marginal zone lymphoma, a type of cancer that targets the immune system.

The 50-patient single-arm, open-label phase 2 study evaluated the safety and efficacy of six cycles of Zynlonta across 18 weeks in patients with relapsed, or refractory marginal zone lymphoma previously treated with one or more line of systemic therapy.

ADC Therapeutics ( ADCT ) said 13 of the 15 patients evaluated, achieved a complete response and one patient achieved a partial response. Patients that achieved responses had maintained them at the time of the data cutoff.

The study showed Zynlonta was "generally well-tolerated and safety was consistent with the known profile," it added. Two patients discontinued the trial after cycle 2 and cycle 4 due to a toxicity, "which fully resolved upon discontinuation of treatment," the company said.

Price: 6.0900, Change: +1.19, Percent Change: +24.29